Adiposity Excess and Vertebral Fractures in Patients With Breast Cancer Taking Aromatase Inhibitors
JAMA Network Open · 30.07.2026 · 9 (7) · e2626450
DOI: 10.1001/jamanetworkopen.2026.26450 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 30.07.2026. Verfasst von Greta Schivardi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health (DSMC), University of Brescia, Brescia, Italy. Hauptthemen laut MEDLINE: Aromatase Inhibitors, Breast Neoplasms, Spinal Fractures, Adiposity. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Aromatase inhibitors (AIs) profoundly suppress estrogen synthesis and accelerate bone loss in postmenopausal women with early breast cancer (EBC). Although body mass index (BMI)–defined obesity has been considered protective for skeletal health, emerging evidence suggests a paradoxical association with fracture risk.
Objective
To evaluate whether fat mass percentage (FM%) greater than 40.8%, measured by dual-energy x-ray absorptiometry (DXA), is associated with vertebral fracture (VF) progression in patients with EBC receiving AIs. Design, Settings, and Participants This retrospective cohort study included consecutive postmenopausal women with EBC (stages I-III) recruited in a single referral center between September 2014 and June 2024. All patients received adjuvant endocrine therapy and underwent serial DXA assessments. Patients treated with tamoxifen or with major comorbidities affecting skeletal fragility were excluded. Exposures Body composition and bone fragility parameters evaluated by DXA at baseline and at 18, 24, and 30 months. Main Outcomes and Measures Adiposity excess was defined as FM% greater than 40.8%, and VF progression was defined as new incident fractures and/or worsening by at least 1 Genant grade at a previously fractured vertebral level. Their association was evaluated using a joint model; time-dependent associations were evaluated using extended Cox regression. Secondary analyses explored associations with bone mineral density, trabecular bone score (TBS), appendicular lean mass index (ALMI), and traditional fracture risk factors.
Results
A total of 769 White women (median [range] age, 63 [30-87] years; median [range] BMI, 24.6 [15.6-46.1]) entered the study. During follow-up, 69 patients (9.0%) experienced VF progression. FM% greater than 40.8% was independently associated with increased VF progression (adjusted hazard ratio [HR], 2.00; 95% CI, 1.44-2.82; P < .001). Higher ALMI (HR, 0.38; 95% CI, 0.22-0.65; P < .001) and BMD (HR, 0.79; 95% CI, 0.66-0.94; P = .01) were associated with lower risk of VF progression. Conclusions and Relevance In this retrospective cohort study of patients with EBC receiving AIs, adiposity excess was identified as a novel fracture risk factor, whereas higher muscle mass was protective. These findings support incorporating body-composition assessment into fracture-risk evaluation and preventive strategies for patients undergoing AI therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health (DSMC), University of Brescia, Brescia, Italy.
- Medical Oncology Unit, ASST Spedali Civili di Brescia Comprehensive Cancer Center, Brescia, Italy.
- Diagnostic Radiology Unit 2, ASST Spedali Civili di Brescia Comprehensive Cancer Center, Brescia, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy.
- Metabolic Bone Diseases and Osteoporosis Section, IRCCS Humanitas Clinical and Research Hospital, Rozzano-Milan, Italy.
- Department of Clinical and Experimental Sciences, Unit of Endocrinology and Metabolism, University of Brescia, Brescia, Italy.
Zitieren
APA
Schivardi, G., Cosentini, D., Scartabellati, G., Ravanelli, M., Moretti, L., Mazziotti, G., Bazzoli, M., Strazzeri, S., Delbarba, A., Grisanti, S., Laganà, M., Turla, A., Chiara, E. D., Cappelli, C., Farina, D., Calza, S., Donato, F., Berruti, A., & Pedersini, R. (2026). Adiposity Excess and Vertebral Fractures in Patients With Breast Cancer Taking Aromatase Inhibitors. JAMA Network Open, 9(7), e2626450. https://doi.org/10.1001/jamanetworkopen.2026.26450
Vancouver
Schivardi G, Cosentini D, Scartabellati G, Ravanelli M, Moretti L, Mazziotti G, et al. Adiposity Excess and Vertebral Fractures in Patients With Breast Cancer Taking Aromatase Inhibitors. JAMA Network Open. 2026;9(7):e2626450. doi:10.1001/jamanetworkopen.2026.26450
BibTeX
@article{Schivardi2026,
author = {Schivardi, Greta and Cosentini, Deborah and Scartabellati, Giulia and Ravanelli, Marco and Moretti, Laura and Mazziotti, Gherardo and Bazzoli, Michela and Strazzeri, Salvatore and Delbarba, Andrea and Grisanti, Salvatore and Laganà, Marta and Turla, Antonella and Chiara, Emanuele Dalla and Cappelli, Carlo and Farina, Davide and Calza, Stefano and Donato, Francesco and Berruti, Alfredo and Pedersini, Rebecca},
title = {Adiposity Excess and Vertebral Fractures in Patients With Breast Cancer Taking Aromatase Inhibitors},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {7},
pages = {e2626450},
doi = {10.1001/jamanetworkopen.2026.26450}
}
EUVIMED